The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
124958564 12495856 4 F 201605 20160825 20160624 20160829 EXP CA-JNJFOC-20160504572 JANSSEN 59.15 YR A M Y 103.87000 KG 20160829 CN CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
124958564 12495856 1 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 0 700 MG LYOPHILIZED POWDER
124958564 12495856 2 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 0 700 MG LYOPHILIZED POWDER
124958564 12495856 3 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 0 700 MG LYOPHILIZED POWDER
124958564 12495856 4 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 0 700 MG LYOPHILIZED POWDER
124958564 12495856 5 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 0 700 MG LYOPHILIZED POWDER
124958564 12495856 6 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 0 700 MG LYOPHILIZED POWDER
124958564 12495856 7 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 0 700 MG LYOPHILIZED POWDER
124958564 12495856 8 PS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y N FKM95011 103772 700 MG LYOPHILIZED POWDER
124958564 12495856 9 C PREDNISONE. PREDNISONE 1 Unknown 0 30 MG UNSPECIFIED
124958564 12495856 10 C RANITIDINE. RANITIDINE 1 Unknown 0 150 MG UNSPECIFIED
124958564 12495856 11 C ROSUVASTATIN. ROSUVASTATIN 1 Unknown 0 10 MG UNSPECIFIED
124958564 12495856 12 C CITALOPRAM CITALOPRAM HYDROBROMIDE 1 Unknown 0 20 MG UNSPECIFIED
124958564 12495856 13 C FERROUS GLUCONATE FERROUS GLUCONATE 1 Unknown 0 300 MG UNSPECIFIED
124958564 12495856 14 C FOLIC ACID. FOLIC ACID 1 Unknown 0 5 MG UNSPECIFIED

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
124958564 12495856 1 Colitis
124958564 12495856 2 Colitis
124958564 12495856 3 Colitis
124958564 12495856 4 Colitis
124958564 12495856 5 Crohn's disease
124958564 12495856 6 Crohn's disease
124958564 12495856 7 Crohn's disease
124958564 12495856 8 Crohn's disease

Outcome of event

Event ID CASEID OUTC COD
124958564 12495856 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
124958564 12495856 Abdominal pain
124958564 12495856 Clostridium difficile infection
124958564 12495856 Diarrhoea
124958564 12495856 Gastrointestinal infection
124958564 12495856 Malaise
124958564 12495856 Osteomyelitis
124958564 12495856 Peripheral embolism
124958564 12495856 Sepsis

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
124958564 12495856 1 20160504 0
124958564 12495856 2 20160706 0
124958564 12495856 3 201606 0
124958564 12495856 4 20160421 0
124958564 12495856 5 201606 0
124958564 12495856 6 20160706 0
124958564 12495856 7 20160421 0
124958564 12495856 8 20160504 0